

INDEPENDENCE
ANNIVERSARY

Sustaining a united and progressive nation:
Taking charge of our future as a free nation



HAPPY Independence Day


The Management and Staff of Dei BioPharma Ltd, a Biotech and Pharma company, wishes to extend our warm wishes to H.E President Yoweri Kaguta Museveni, the National Resistance Movement party and all Ugandans on the occasion of Uganda's Independence Day Celebrations. The commemoration of Uganda's independence infuse the heart of each and every Ugandan citizen with love for their country. As Dei BioPharma Ltd, we seek to promote Uganda's self-reliance by producing latest cancer drugs, biologics, biosimilars, gene therapy and therapeutic proteins yet very affordable to cure diseases which affect millions of people across Uganda and Africa.

This day will always be the occasion of greatest pride for each one of us.

Management

Dei BioPharma Ltd.





**INDEPENDENCE
ANNIVERSARY**

**Sustaining a united and progressive nation:
Taking charge of our future as a free nation**

THE NUMBER

40,000

Jobs expected to be created directly in the value chain.

3,000

Formulations secured and capable of producing a wide range of potential drugs, vaccines, anti-cancer drugs,

1bn

Vaccines doses. of mRNA vaccines to be produced at this facility guided by World Health Organization standards.



President Y.K. Museveni and his Kenyan counterpart William Ruto commissioned the project in 2021, and were optimistic this would propel Africa's capacity.

Facts about Dei BioPharma's vaccines plant in Uganda

Low cost drugs. The multi-million dollar biological drugs and vaccines manufacturing facility in Matugga, Wakiso, Uganda being developed by Dei Biopharma Ltd, a company under the DEI Group headed by Mr. Matthias Magoola, a professional chemist is expected to produce vaccines, including latest cancer drugs, malaria treatment medicines, with incidents of the later on increase and the former being Africa's biggest killer.

Background

The Dei Bio Pharma Drugs and Vaccines Manufacturing Plant, which is located at Matugga in Wakiso District, was launched on July 6, 2021, by President Yoweri Museveni and then Kenyan Vice President (now President) William Ruto.

The facility, built at a cost of USD 1 billion, seeks to produce high quality yet affordable medicines, including those of cancer and malaria that will make a difference to millions of families across Africa.

The facility is also the only African pharmaceutical company manufacturing the Covid-19 therapeutic medications and gearing to produce one billion doses of an mRNA vaccines guided by World Health Organization (WHO) standards.

At the launch, the two leaders expressed optimism that the construction of the facility, would concretise efforts to make Africa self-sustaining in healthcare.

Vice President (now President) Ruto said: "It is very reassuring that people of this continent and especially East Africans like Mr Mathias Magoola are turning challenges into opportunities. With this facility, Af-

WHO WE ARE

Dei BioPharma Uganda Ltd is a Biotech and Pharma Research Company incorporated in Uganda in January 2014 that produces medicines, food supplements and cosmetics.

Dei BioPharma Uganda is part of Dei Group of Companies that offers a wide range of businesses, which include wheat processing, technology, and pharmaceuticals.

OUR VISION

To create business opportunities and solutions for Africa through production of quality medicines using the latest innovative processes. To be the most preferred partner of choice of contract manufacturing and pharmaceutical branding

OUR MISSION

We aspire to become a globally acclaimed pharmaceutical company that produces a diverse portfolio of vaccines and low cost drugs, which treat diseases that afflict most people. We also seek to empower Africa through innovation, research, manufacturing and technology.

rica will produce medicines to supply not only Africa but the globe. It's gratifying that Africa can no longer be a source of problems but solutions."

Dei Group Managing Director Mathias Magoola said they secured more than 3,000 formulations giving it a wide array of potential drugs for production, vaccines, anti-cancer drugs, therapeutic proteins, peptides and cell therapy, among others.

Our Products

Under the facility that stands on 150 acres of land, Dei Biopharma Ltd will make the vital drugs for the continent including all types of vaccines on top of the mRNA vaccines, and other biological solutions listed as essential drugs including the Filgrastim, Erythropoietin, and Trastuzumab, among several others, is the first such source of biosimilars in Africa, according to experts.

On top of the mRNA vaccines, which is the only component being put up by Mordena in Kenya, the Dei Biopharma Ltd Ugandan facility will manufacture:-

1. Inactivated vaccines (used to protect against:- Hepatitis A- Flu (shot only)- Polio (shot only)- Rabies).

2. Live-attenuated vaccines (used to protect against:- Mea-

sles, mumps, rubella (MMR combined vaccine)- Rotavirus- Smallpox- Chickenpox Yellow fever).

3. Messenger RNA (mRNA) vaccines (used to protect against:- COVID-19).

4. Subunit, recombinant, polysaccharide, and conjugate vaccines (used to protect against:- Hib (Haemophilus influenzae type b) disease- Hepatitis B- HPV (Human papillomavirus)- Whooping cough (part of the DTaP combined vaccine)- Pneumococcal disease- Meningococcal disease Shingles).

5. Toxoid vaccines (used to protect against Diphtheria Tetanus).

6. Viral vector vaccines (used to protect against:- COVID-19).


On top of that, Dei Biopharma has an offtake agreement with the Government of Uganda to manufacture the different types of drugs that the government is currently importing and to hit that target, Dei Biopharma has established the following facilities in the project;

- 1- The Generics section
- 2 - The Nutraceuticals section
- 3- The Oncology/cancer drugs
- 4- Penicillin section
- 5- The Cephalosporins section
- 6- Non Beta lactum section
- 7- The Injectable facilities
- 8- The WFI facility
- 9- The Parentals
- 10- The Ophthalmic facility

On top of the above, Dei Biopharma Ltd has also set up the iconic YKTM GLP Biotech Laboratories that includes the following components :- Cancer research, QA/QC, drug discovery, Gene therapy, Cell therapy, mRNA therapeutics, vaccines, Biologics, Biosimilars and therapeutic protein.

The facility will, importantly, have biological facilities to manufacture biological drugs, biosimilars, cytokines, therapeutic protein, peptides and monoclonal antibodies.

The above is what makes this facility so unique and is the reason, it will cost us more than \$1 billion.



The iconic YKTM GLP Biotech Laboratories

“

Expected direct benefits to Ugandans?

Our plan is to manufacture pharmaceutical grade starch and advanced starch which is usually 40 times more expensive than PHARMA grade starch from cassava, potatoes and maize. This will create such a huge market for the farmers.

Mr. Magoola says.